Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock
SHPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.24−0.29 (-6.40%)
Close on Nov 16, 2026Market cap $4.24MP/E –Yield –
Shuttle Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Shuttle Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.78M, down 64.3% year over year. For fiscal 2025 it was $4.05M, up 12.0% from the year before. The highest annual figure on record is $4.05M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.05M | +12.0% |
| FY2024 | Dec 31, 2024 | $3.62M | +2.9% |
| FY2023 | Dec 31, 2023 | $3.52M | +235.8% |
| FY2022 | Dec 31, 2022 | $1.05M | +2.5% |
| FY2021 | Dec 31, 2021 | $1.02M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $55.66K | -94.6% |
| Q1 FY2026 | Mar 31, 2026 | $267.24K | -83.0% |
| Q4 FY2025 | Dec 31, 2025 | $511.88K | -48.1% |
| Q3 FY2025 | Sep 30, 2025 | $943.48K | -32.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.03M | +58.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.57M | +168.5% |
| Q4 FY2024 | Dec 31, 2024 | $986.41K | +38.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.40M | +34.0% |
| Q2 FY2024 | Jun 30, 2024 | $645.72K | -23.1% |
| Q1 FY2024 | Mar 31, 2024 | $586.10K | -36.4% |
| Q4 FY2023 | Dec 31, 2023 | $710.45K | +611.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.05M | +56.2% |
| Q2 FY2023 | Jun 30, 2023 | $839.67K | +901.2% |
| Q1 FY2023 | Mar 31, 2023 | $921.80K | +211.5% |
| Q4 FY2022 | Dec 31, 2022 | $99.89K | -77.4% |
| Q3 FY2022 | Sep 30, 2022 | $669.04K | +257.9% |
| Q2 FY2022 | Jun 30, 2022 | $83.87K | – |
| Q1 FY2022 | Mar 31, 2022 | $295.92K | – |
| Q4 FY2021 | Dec 31, 2021 | $442.12K | – |
| Q3 FY2021 | Sep 30, 2021 | $186.96K | – |
See a number that looks wrong?